Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BID | P55957 | 3/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.52 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.52 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.52 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 3/20 | 0.46 |
| ▸ | F3 | P13726 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11125907 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| SCHEMBL31372911 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| Zinc Ion SCHEMBL7084049 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| Zinc Ion SCHEMBL10581371 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| Zinc Ion SCHEMBL10584384 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| SCHEMBL9790326 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| SCHEMBL11123537 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| SCHEMBL11169533 | 0.97 | BID (0.52) | BIDMCL1PPARABCL2L1BAK1 | |
| SCHEMBL8625728 | 0.91 | IAPP (0.48) | BIDMCL1PPARABCL2L1BAK1 | |
| SCHEMBL1640151 | 0.91 | IAPP (0.48) | BIDMCL1PPARABCL2L1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200613-B1 | PHENAZINE DERIVATIVES AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2018-09-05 | — | — | EP | disclosed |
| US-8669257-B2 | Phenazine derivatives and uses thereof as potassium channel modulators | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20100330156-A1 | PHENAZINE DERIVATIVES AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2200613-A2 | PHENAZINE DERIVATIVES AND USES THEREOF | The Johns Hopkins University (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090227606-A1 | Methods for Preventing or Treating Acute and Chronic Pain | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-09-10 | — | — | US | disclosed |
| WO-2009042114-A2 | PHENAZINE DERIVATIVES AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-2023932-A1 | METHODS FOR PREVENTING OR TREATING ACUTE AND CHRONIC PAIN | Trustees of Dartmouth College (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007137214-A1 | METHODS FOR PREVENTING OR TREATING ACUTE AND CHRONIC PAIN | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330156-A1 | PHENAZINE DERIVATIVES AND USES THEREOF | CYP3A5, CYP3A43, CYP4Z1 | BID 2067/4885MCL1 1504/4885PPARA 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.